Top-Rated StocksTop-RatedNASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $6.35 +0.07 (+1.11%) Closing price 04:00 PM EasternExtended Trading$6.42 +0.08 (+1.18%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get EYPT alerts:Sign Up Key Stats Today's Range$6.03▼$6.4450-Day Range$6.27▼$9.2252-Week Range$5.90▼$30.78Volume716,762 shsAverage Volume887,138 shsMarket Capitalization$433.39 millionP/E RatioN/ADividend YieldN/APrice Target$26.63Consensus RatingBuy Company OverviewEyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Read More… EyePoint Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks31st Percentile Overall ScoreEYPT MarketRank™: EyePoint Pharmaceuticals scored higher than 31% of companies evaluated by MarketBeat, and ranked 808th out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyePoint Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about EyePoint Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.13) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about EyePoint Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.71% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently increased by 1.32%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.71% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently increased by 1.32%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.60 News SentimentEyePoint Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 10 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat Follows3 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.74% of the stock of EyePoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about EyePoint Pharmaceuticals' insider trading history. Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Stock News HeadlinesScotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)February 7, 2025 | markets.businessinsider.comEyePoint Announces Positive 6-Month Data From Duravyu Trial For Diabetic Macular EdemaFebruary 6, 2025 | markets.businessinsider.comMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.February 12, 2025 | Colonial Metals (Ad)EyePoint stock jumps 10% on Duravyu study resultsFebruary 6, 2025 | msn.comEyePoint Pharmaceuticals Stock Gains 3% After Positive Phase 2 Trial ResultsFebruary 6, 2025 | markets.businessinsider.comCollegium appoints Nancy Lurker to board of directorsFebruary 5, 2025 | markets.businessinsider.comDURAVYU shows promise in Phase 2 trial for eye diseaseFebruary 5, 2025 | msn.comEyePoint's decline following positive data makes no sense, says analystFebruary 5, 2025 | investing.comSee More Headlines EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? EyePoint Pharmaceuticals' stock was trading at $7.45 at the beginning of the year. Since then, EYPT shares have decreased by 14.8% and is now trading at $6.35. View the best growth stocks for 2025 here. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.06. The business had revenue of $10.52 million for the quarter, compared to the consensus estimate of $12.35 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative trailing twelve-month return on equity of 43.01%. When did EyePoint Pharmaceuticals' stock split? EyePoint Pharmaceuticals's stock reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are EyePoint Pharmaceuticals' major shareholders? Top institutional shareholders of EyePoint Pharmaceuticals include Franklin Resources Inc. (6.06%), Vanguard Group Inc. (5.57%), Geode Capital Management LLC (2.25%) and JPMorgan Chase & Co. (0.58%). Insiders that own company stock include Ew Healthcare Partners, LP, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine and David R Guyer. View institutional ownership trends. How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that EyePoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings11/07/2024Today2/12/2025Next Earnings (Estimated)3/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees120Year Founded1987Price Target and Rating Average Stock Price Target$26.63 High Stock Price Target$33.00 Low Stock Price Target$15.00 Potential Upside/Downside+329.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,790,000.00 Net Margins-226.57% Pretax Margin-226.38% Return on Equity-43.01% Return on Assets-31.63% Debt Debt-to-Equity RatioN/A Current Ratio5.50 Quick Ratio5.45 Sales & Book Value Annual Sales$46.02 million Price / Sales9.19 Cash FlowN/A Price / Cash FlowN/A Book Value$5.66 per share Price / Book1.10Miscellaneous Outstanding Shares68,250,000Free Float65,016,000Market Cap$423.15 million OptionableOptionable Beta1.51 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:EYPT) was last updated on 2/12/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored New Options "Trading GPS" = 91% Win-RateThink of it as GPS navigation for the options market... Even traders who previously found options "too comp...Eagle Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | Sponsored$589 billion wiped out overnightYou need to watch this before you invest another cent in AI. Because more than $589 billion was wiped out o...Porter & Company | SponsoredElon has entered the MarkBeat conversationSpivey's firm accurately warned of both the 2008 and 2020 stock market crashes and have charged institutional ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.